On 25 August 2026 Solvonis raised £1.3m gross in a placing at £0.0012 per share, a 14% discount to the prior close, appointing Turner Pope Investments as sole broker and adding a UK institutional investor to the register, taking shares in issue to around …
On 28 July 2026 GSK (LSE:GSK) reported second-quarter total sales of £8.4bn, up 5%, and core operating profit of around £2.8bn. The company raised its research ambition, now planning more than 20 Phase III trial starts in 2026 across sevenAssetsand 18 indications in oncology, …
In February 2026 AstraZeneca (LSE:AZN) began trading directly on the New York Stock Exchange, giving what it called “equal weight” to its UK, Swedish and US listings while keeping London as its primary listing — a move accompanying a reaffirmed pledge to invest $50bn …
Digital mental health has been a volatile place to invest, and Kooth (LSE: KOO) has embodied both the promise and the pitfalls. The company provides anonymous online mental-health support in the UK and, through its Soluna app, to young people across California under a …
Commercial-stage pharmaceutical company Shield Therapeutics (AIM: STX) has handed the market a clear, fundamental catalyst. On 27 August 2026 it announced that it would take full commercial control of its lead product, the oral iron therapy ACCRUFeR, in the United States — and the …
Smith & Nephew, the London-listed medical-technology group behind artificial hips and knees, sports-medicine tools and advanced wound-care dressings, has spent several years trying to convince investors that its long-promised turnaround is real. Its second-quarter and half-year results on 4 August 2026 delivered a mixed …
ConvaTec, the Reading-based FTSE 100 medical-technology group, has quietly transformed itself over the past few years from a sleepy chronic-care supplier into a more disciplined, faster-growing medtech business. Its products address unglamorous but essential needs — advanced wound care, ostomy care, continence care and …
AstraZeneca is Britain's most valuable listed company, and with a market capitalisation in the region of £193 billion it carries an outsized influence over the FTSE 100. For all that heft, the investment case rests on a single, demanding proposition: that chief executive Pascal …
GSK is opening a new chapter. After nearly a decade with Emma Walmsley at the helm — a period that saw the demerger of consumer-health business Haleon and a rebuilding of the pipeline — the FTSE 100 pharmaceutical group is transitioning to newLeadershipunder Luke …
Haleon does not generate the headlines of a Diageo or a Vodafone, but the consumer-health group spun out of GSK in 2022 has become one of the FTSE 100's steadier performers. The owner of Sensodyne, Panadol, Centrum, Voltaren, Advil and parodontax sits at the …